

Yusuf Yilmaz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6943777/publications.pdf>

Version: 2024-02-01

174
papers

9,368
citations

87723

38
h-index

45213

90
g-index

177
all docs

177
docs citations

177
times ranked

9715
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. <i>Gut</i> , 2022, 71, 1006-1019.	6.1	195
2	A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1456-e1468.	2.4	49
3	Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 329-338.	0.7	49
4	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	8.2	330
5	Global multi-stakeholder endorsement of the MAFLD definition. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 388-390.	3.7	135
6	A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 345-352.	1.4	41
7	Tryptanthrin from microwave-assisted reduction of isatin using solid-state-supported sodium borohydride: DFT calculations, molecular docking and evaluation of its analgesic and anti-inflammatory activity. <i>Heliyon</i> , 2021, 7, e05756.	1.4	16
8	Macro- and micronutrients in metabolic (dysfunction) associated fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, Publish Ahead of Print, .	0.8	5
9	Recommendations for Reopening Endoscopy Units in Turkey: A Set-up Plan from a Tertiary Center in Istanbul. <i>Turkish Journal of Gastroenterology</i> , 2021, 32, 113-115.	0.4	0
10	Liver stiffness is associated with disease severity and worse clinical scenarios in coronavirus disease 2019: A prospective transient elastography study. <i>International Journal of Clinical Practice</i> , 2021, 75, e14363.	0.8	7
11	Administrative Coding in Electronic Health Care Record-Based Research of NAFLD: An Expert Panel Consensus Statement. <i>Hepatology</i> , 2021, 74, 474-482.	3.6	102
12	Feasibility of Fibroscan in Assessment of Hepatic Steatosis and Fibrosis in Obese Patients: Report From a General Internal Medicine Clinic. , 2021, 32, 466-472.		5
13	Evaluation of the Impact of Metabolic Syndrome on Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease. , 2021, 32, 661-666.		4
14	acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study. <i>EClinicalMedicine</i> , 2021, 41, 101145.	3.2	14
15	Demographic Characteristics and Transmission Risk Factors of Patients with Hepatitis C Virus in Turkey: The EPI-C, A Multicenter and Cross-sectional Trial. <i>Viral Hepatitis Journal</i> , 2021, 27, 109-117.	0.1	0
16	Editorial: liver stiffness by magnetic resonance elastography and cardiovascular risk in non-alcoholic fatty liver disease—simply associated or more complicated?. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1228-1229.	1.9	1
17	NFS Is Not a Marker of Nonalcoholic Fatty Liver Disease Per Se: What Is the True Relationship With CAD Complexity?. <i>Angiology</i> , 2020, 71, 83-84.	0.8	1
18	The interaction between current smoking and hemoglobin on the risk of advanced fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 597-600.	0.8	5

#	ARTICLE	IF	CITATIONS
19	The diagnostic utility of fibrosis-4 or nonalcoholic fatty liver disease fibrosis score combined with liver stiffness measurement by fibroscan in assessment of advanced liver fibrosis: a biopsy-proven nonalcoholic fatty liver disease study. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 642-649.	0.8	24
20	Arterial stiffness is associated independently with liver stiffness in biopsy-proven nonalcoholic fatty liver disease: a transient elastography study. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 54-57.	0.8	11
21	Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease. <i>Acta Diabetologica</i> , 2020, 57, 613-618.	1.2	41
22	The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. <i>Hepatology International</i> , 2020, 14, 889-919.	1.9	422
23	A DFT/TD-DFT study on the possible replacement of Ru(II) with Fe(II) in phthalocyanine-based dye-sensitized solar cells. <i>Structural Chemistry</i> , 2020, 31, 2301-2311.	1.0	3
24	Supramolecular architecture in 1:1 cocrystal of N-carbamothioylacetamide and N,Nâ€²-thiocarbonyldiacetamide from the attempted synthesis of 1,3-diacetyl-2-thioxoimidazolidine-4,5-dione (a thioparabanic acid derivative). <i>Heliyon</i> , 2020, 6, e05022.	1.4	1
25	Impact of aerobic training with and without whole-body vibration training on metabolic features and quality of life in non-alcoholic fatty liver disease patients. <i>Annales D'Endocrinologie</i> , 2020, 81, 493-499.	0.6	9
26	Role of intensive dietary and lifestyle interventions in the treatment of lean nonalcoholic fatty liver disease patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1352-1357.	0.8	37
27	Anticancer Activity Study and Density Functional/Time-Dependent Density Functional Theory (DFT/TD-DFT) Calculations of 2(3),9(10),16(17),23(24)-Tetrakis-(6-Methylpyridin-2-Yloxy)Phthalocyaninato Zn(II). <i>Journal of Fluorescence</i> , 2020, 30, 1151-1160.	1.3	3
28	External validation of the Toronto hepatocellular carcinoma risk index in Turkish cirrhotic patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 882-888.	0.8	7
29	Letter: a stepwise approach towards the screening of hepatic fibrosis in the general population. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 669-670.	1.9	2
30	FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 362-373.	3.7	411
31	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , 2020, 73, 202-209.	1.8	2,171
32	Accuracy of Fibrosis-4 index and non-alcoholic fatty liver disease fibrosis scores in metabolic (dysfunction) associated fatty liver disease according to body mass index. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, Publish Ahead of Print, 98-103.	0.8	33
33	Simple Noninvasive Scores Are Clinically Useful to Exclude, Not Predict, Advanced Fibrosis: A Study in Turkish Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2020, 14, 486-491.	1.4	51
34	Letter: the perilous road to a functional cure for hepatitis B infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 577-577.	1.9	0
35	Effect of carbon dioxide versus room air insufflation on post-colonoscopy pain: A prospective, randomized, controlled study. <i>Turkish Journal of Gastroenterology</i> , 2020, 31, 676-680.	0.4	2
36	Letter: the use of Fibrosisâ€”4 score in primary care and diabetology practicesâ€”Occamâ€™s razor applied to advanced fibrosis screening. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1759-1760.	1.9	7

#	ARTICLE	IF	CITATIONS
37	Antidiabetic and antioxidant activities: Is there any link between them?. <i>New Journal of Chemistry</i> , 2019, 43, 13326-13329.	1.4	12
38	Hepatic fibrosis " and not steatosis " is the main determinant of arterial stiffness in non-alcoholic fatty liver disease. <i>Atherosclerosis</i> , 2019, 290, 222-223.	0.4	2
39	Potential clinical variants detected in mitochondrial DNA D-loop hypervariable region I of patients with non-alcoholic steatohepatitis. <i>Hormones</i> , 2019, 18, 463-475.	0.9	8
40	Synthesis and spectroscopic characterization of new phthalocyanine derivatives: application as photocatalysts for the degradation of Orange G. <i>Turkish Journal of Chemistry</i> , 2019, 43, 1006-1016.	0.5	2
41	Serum biomarkers of fibrosis and extracellular matrix remodeling in patients with nonalcoholic fatty liver disease: association with liver histology. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 43-46.	0.8	43
42	Asymmetric phthalocyanines conjugated on silica for the photocatalytic degradation of organic pollutants synthesis, characterization and investigation of the photophysicochemical properties. <i>Main Group Chemistry</i> , 2019, 18, 31-42.	0.4	6
43	An approximate procedure for profiling dye molecules with potentials as sensitizers in solar cell application: A DFT/TD-DFT approach. <i>Chemical Physics Letters</i> , 2019, 723, 111-117.	1.2	12
44	Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1625-1633.e1.	2.4	107
45	Comments on "The Effect of Laparoscopic Sleeve Gastrectomy on Nonalcoholic Fatty Liver Disease": Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2019, 29, 548-548.	0.4	0
46	Transient elastography for assessing severe hepatic fibrosis in diabetic patients with nonalcoholic fatty liver disease: definitions matter. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1601-1602.	0.8	0
47	Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2019, 69, 2672-2682.	3.6	1,203
48	Characterization of Patients with Biopsy-Proven Non-Alcoholic Fatty Liver Disease and Normal Aminotransferase Levels. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 427-431.	0.5	32
49	Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience. <i>Revista Da Associação Médica Brasileira</i> , 2019, 65, 1470-1475.	0.3	5
50	Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: A transient elastography study. <i>Turkish Journal of Gastroenterology</i> , 2019, 30, 266-270.	0.4	20
51	Non-alcoholic fatty liver disease: A growing public health problem in Turkey. <i>Turkish Journal of Gastroenterology</i> , 2019, 30, 865-871.	0.4	30
52	Evaluation of depression, anxiety and quality of life in hepatitis C patients who treated with direct acting antiviral agents. <i>Turkish Journal of Gastroenterology</i> , 2019, 30, 801-806.	0.4	13
53	Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience. <i>Turkish Journal of Gastroenterology</i> , 2019, 30, 892-898.	0.4	24
54	Prevalence of fatty liver disease in patients with inflammatory bowel disease: a transient elastography study on the basis of a controlled attenuation parameter. <i>Marmara Medical Journal</i> , 2019, 32, 68-70.	0.2	4

#	ARTICLE	IF	CITATIONS
55	The association of fatty pancreas with subclinical atherosclerosis in nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 411-417.	0.8	23
56	Microwave-assisted synthesis, structural characterization, DFT studies, antibacterial and antioxidant activity of 2-methyl-4-oxo-1,2,3,4-tetrahydroquinazoline-2-carboxylic acid. <i>Journal of Molecular Structure</i> , 2018, 1155, 610-622.	1.8	9
57	Isolation, characterization, crystal structure, free radical scavenging- and computational studies of 9-[4-(propan-2-yl)phenyl]-3,4,5,6,7,9-hexahydro-1H-xanthene-1,8(2H)-dione from <i>Garcinia kola</i> seeds. <i>Journal of Molecular Structure</i> , 2017, 1144, 396-405.	1.8	3
58	The association of nonalcoholic fatty liver disease with genetic polymorphisms: a multicenter study. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 441-447.	0.8	21
59	Nonalcoholic steatohepatitis and gut microbiota: Future perspectives on probiotics in metabolic liver diseases. <i>Turkish Journal of Gastroenterology</i> , 2017, 28, 327-328.	0.4	6
60	Recommendation for treatment of hepatitis C virus infection. <i>Turkish Journal of Gastroenterology</i> , 2017, 28, 94-100.	0.4	7
61	Diagnostic Role of Colon Capsule Endoscopy in Patients with Optimal Colon Cleaning. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-5.	0.7	5
62	Prevalence of hepatic steatosis in apparently healthy medical students: a transient elastography study on the basis of a controlled attenuation parameter. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 1264-1267.	0.8	18
63	Synthesis and Crystal Structure of a New Phthalonitrile and Its Phthalocyanines Bearing Diamagnetic Metals. <i>Synthesis and Reactivity in Inorganic, Metal Organic, and Nano Metal Chemistry</i> , 2016, 46, 110-117.	0.6	7
64	Nonlinear optical behavior of alkyne terminated phthalocyanines in solution and when embedded in polysulfone as thin films: Effects of aggregation. <i>Optical Materials</i> , 2016, 51, 194-202.	1.7	11
65	Synthesis and characterization of novel phthalocyanines and evaluation of photodynamic therapy properties. <i>Proceedings of SPIE</i> , 2016, , .	0.8	1
66	Comparison of Doppler ultrasound and transient elastography in the diagnosis of significant fibrosis in patients with nonalcoholic steatohepatitis. <i>Abdominal Radiology</i> , 2016, 41, 1505-1510.	1.0	8
67	The role of active brown adipose tissue in human metabolism. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 355-361.	3.3	22
68	Measurements of serum procollagen-III peptide and M30 do not improve the diagnostic accuracy of transient elastography for the detection of hepatic fibrosis in patients with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 667-671.	0.8	10
69	Nonalcoholic Steatohepatitis Score is an Independent Predictor of Right Ventricular Dysfunction in Patients with Nonalcoholic Fatty Liver Disease. <i>Cardiovascular Therapeutics</i> , 2015, 33, 294-299.	1.1	22
70	Diagnostic usefulness of FibroMeter VCTE for hepatic fibrosis in patients with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 1149-1153.	0.8	21
71	Synthesis and Photoluminescence Properties of Saccharide Conjugated Copper Phthalocyanine via Click Reaction. <i>Synthesis and Reactivity in Inorganic, Metal Organic, and Nano Metal Chemistry</i> , 2015, 45, 337-341.	0.6	3
72	Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 341-346.	0.6	74

#	ARTICLE	IF	CITATIONS
73	Comparison of noninvasive scores for the detection of advanced fibrosis in patients with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 137-141.	0.8	36
74	Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2015, 21, 8096.	1.4	8
75	No association between the functional cannabinoid receptor type 2 Q63R variants and inflammatory bowel disease in Turkish subjects. <i>Turkish Journal of Gastroenterology</i> , 2015, 25, 639-43.	0.4	6
76	Gallstone Disease Does Not Predict Liver Histology in Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2014, 8, 313-317.	1.4	28
77	A comparison of FibroMeter [®] , [†] NAFLD Score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 1343-1348.	0.6	43
78	Diphenylethoxy-substituted metal-free and metallophthalocyanines as potential photosensitizer for photodynamic therapy: synthesis and photophysical and photochemical properties. <i>Turkish Journal of Chemistry</i> , 2014, 38, 1083-1093.	0.5	6
79	Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis. <i>PLoS Medicine</i> , 2014, 11, e1001680.	3.9	507
80	A Bayesian approach to an integrated multimodal noninvasive diagnosis of definitive nonalcoholic steatohepatitis in the spectrum of nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 1292-1295.	0.8	7
81	Obesity-Associated Nonalcoholic Fatty Liver Disease. <i>Clinics in Liver Disease</i> , 2014, 18, 19-31.	1.0	75
82	Photophysical and photochemical properties and TD-DFT calculations of novel zinc and platinum phthalocyanines. <i>Journal of Photochemistry and Photobiology A: Chemistry</i> , 2014, 277, 102-110.	2.0	15
83	Arterial stiffness in patients with non-alcoholic fatty liver disease is related to fibrosis stage and epicardial adipose tissue thickness. <i>Atherosclerosis</i> , 2014, 237, 490-493.	0.4	67
84	Can Enhanced Autophagy Be Associated with Human Longevity? Serum Levels of the Autophagy Biomarker Beclin-1 Are Increased in Healthy Centenarians. <i>Rejuvenation Research</i> , 2014, 17, 518-524.	0.9	43
85	Not only type 2 diabetes but also prediabetes is associated with portal inflammation and fibrosis in patients with non-alcoholic fatty liver disease. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 328-331.	1.2	17
86	Detection of hepatic steatosis using the controlled attenuation parameter: a comparative study with liver biopsy. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 611-616.	0.6	31
87	Photophysicochemical properties and TD-DFT calculations of a novel terminal alkyne substituted metal free phthalocyanine. <i>Journal of Porphyrins and Phthalocyanines</i> , 2014, 18, 251-258.	0.4	1
88	Synthesis, photophysicochemical properties and TD-DFT calculations of tetrakis(2-benzoyl-4-chlorophenoxy) phthalocyanines. <i>Journal of Porphyrins and Phthalocyanines</i> , 2014, 18, 326-335.	0.4	2
89	Liver disease and malnutrition. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2013, 27, 619-629.	1.0	50
90	Assessment of endothelial function in patients with nonalcoholic fatty liver disease. <i>Endocrine</i> , 2013, 43, 100-107.	1.1	72

#	ARTICLE	IF	CITATIONS
91	Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2013, 45, 58-62.	0.4	21
92	Noninvasive detection of hepatic steatosis in patients without ultrasonographic evidence of fatty liver using the controlled attenuation parameter evaluated with transient elastography. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 1330-1334.	0.8	32
93	Linking Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: From Bedside to Bench and Back. <i>Tumori</i> , 2013, 99, 10-16.	0.6	10
94	Biomarkers for Early Detection of Non-Alcoholic Steatohepatitis: Implications for Drug Development and Clinical Trials. <i>Current Drug Targets</i> , 2013, 14, 1357-1366.	1.0	11
95	Circulating vaspin and its relationship with insulin sensitivity, adiponectin and liver histology in subjects with non-alcoholic steatohepatitis. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 489-490.	0.6	1
96	NAFLD in the Absence of Metabolic Syndrome: Different Epidemiology, Pathogenetic Mechanisms, Risk Factors for Disease Progression?. <i>Seminars in Liver Disease</i> , 2012, 32, 014-021.	1.8	45
97	Serum concentrations of human insulin-like growth factor-1 and levels of insulin-like growth factor-binding protein-5 in patients with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 255-261.	0.8	40
98	Identification of a support vector machine-based biomarker panel with high sensitivity and specificity for nonalcoholic steatohepatitis. <i>Clinica Chimica Acta</i> , 2012, 414, 154-157.	0.5	16
99	Unconjugated hyperbilirubinemia and liver histology in patients with non-alcoholic fatty liver disease. <i>Clinical Biochemistry</i> , 2012, 45, 515.	0.8	0
100	Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease. <i>Clinical Biochemistry</i> , 2012, 45, 655-658.	0.8	43
101	Nonalcoholic Fatty Liver Disease: A Nutritional Approach. <i>Metabolic Syndrome and Related Disorders</i> , 2012, 10, 161-166.	0.5	22
102	Serum proteomics for biomarker discovery in nonalcoholic fatty liver disease. <i>Clinica Chimica Acta</i> , 2012, 413, 1190-1193.	0.5	12
103	Research update for articles published in EJCI in 2010. <i>European Journal of Clinical Investigation</i> , 2012, 42, 1149-1164.	1.7	1
104	Hepatic expression and serum levels of syndecan 1 (CD138) in patients with nonalcoholic fatty liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 1488-1493.	0.6	19
105	Concentrations of Connective Tissue Growth Factor in Patients with Nonalcoholic Fatty Liver Disease: Association with Liver Fibrosis. <i>Disease Markers</i> , 2012, 33, 77-83.	0.6	13
106	Is nonalcoholic fatty liver disease the hepatic expression of the metabolic syndrome?. <i>World Journal of Hepatology</i> , 2012, 4, 332.	0.8	20
107	Characterization of nonalcoholic fatty liver disease unrelated to the metabolic syndrome. <i>European Journal of Clinical Investigation</i> , 2012, 42, 411-418.	1.7	37
108	Is M65 really better than M30 as a biomarker of hepatic fibrosis?. <i>Hepatology</i> , 2012, 55, 654-654.	3.6	2

#	ARTICLE	IF	CITATIONS
109	The impact of early percutaneous endoscopic gastrostomy placement on treatment completeness and nutritional status in locally advanced head and neck cancer patients receiving chemoradiotherapy. <i>European Archives of Oto-Rhino-Laryngology</i> , 2012, 269, 275-282.	0.8	33
110	Concentrations of connective tissue growth factor in patients with nonalcoholic fatty liver disease: association with liver fibrosis. <i>Disease Markers</i> , 2012, 33, 77-83.	0.6	7
111	Serum osteocalcin levels in patients with nonalcoholic fatty liver disease: Association with ballooning degeneration. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2011, 71, 631-636.	0.6	39
112	Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2011, 46, 91-97.	0.6	107
113	Serum pigment epithelium-derived factor levels are increased in patients with biopsy-proven nonalcoholic fatty liver disease and independently associated with liver steatosis. <i>Clinica Chimica Acta</i> , 2011, 412, 2296-2299.	0.5	14
114	Cytokeratins in hepatitis. <i>Clinica Chimica Acta</i> , 2011, 412, 2031-2036.	0.5	13
115	Circulating vaspin levels and epicardial adipose tissue thickness are associated with impaired coronary flow reserve in patients with nonalcoholic fatty liver disease. <i>Atherosclerosis</i> , 2011, 217, 125-129.	0.4	53
116	Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2011, 60, 544-549.	1.5	61
117	Reply to Aydin et al: "To what extent is it right to measure serum vaspin, obestatin, and apelin-36 levels without a protease inhibitor in nonalcoholic fatty liver disease?" <i>Metabolism: Clinical and Experimental</i> , 2011, 60, e2.	1.5	1
118	Circulating Levels of Vascular Endothelial Growth Factor A and Its Soluble Receptor in Patients with Biopsy-proven Nonalcoholic Fatty Liver Disease. <i>Archives of Medical Research</i> , 2011, 42, 38-43.	1.5	14
119	Multimarker Strategies for Detecting NASH and NASH-Related Fibrosis: Promises and Caveats. <i>Obesity Surgery</i> , 2011, 21, 1316-1317.	1.1	0
120	Apoptosis: why and how does it occur in biology?. <i>Cell Biochemistry and Function</i> , 2011, 29, 468-480.	1.4	180
121	Serum galectin-3 levels in patients with nonalcoholic fatty liver disease. <i>Clinical Biochemistry</i> , 2011, 44, 955-958.	0.8	10
122	Serum zinc- α 2-glycoprotein concentrations in patients with non-alcoholic fatty liver disease. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 93-7.	1.4	13
123	Protective Effect of the Vasopressin Agonist Terlipressin in a Rat Model of Contrast-Induced Nephropathy. <i>American Journal of Nephrology</i> , 2011, 33, 269-276.	1.4	10
124	Serum Levels of Hepcidin in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease. <i>Metabolic Syndrome and Related Disorders</i> , 2011, 9, 287-290.	0.5	44
125	Kefir Improves the Efficacy and Tolerability of Triple Therapy in Eradicating <i>Helicobacter pylori</i> . <i>Journal of Medicinal Food</i> , 2011, 14, 344-347.	0.8	70
126	Serum Progranulin as an Independent Marker of Liver Fibrosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease. <i>Disease Markers</i> , 2011, 31, 205-210.	0.6	24

#	ARTICLE	IF	CITATIONS
127	Serum progranulin as an independent marker of liver fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease. <i>Disease Markers</i> , 2011, 31, 205-10.	0.6	19
128	Plasma Fibrinogen-Like Protein 2 Levels in Patients with Non-Alcoholic Fatty Liver Disease. <i>Hepato-Gastroenterology</i> , 2011, 58, 2087-90.	0.5	12
129	Plasma prohepcidin levels in patients with chronic viral hepatitis: relationship with liver fibrosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 461-465.	0.8	9
130	The AGEs-RAGE axis and nonalcoholic steatohepatitis: the evidence mounts. <i>Journal of Gastroenterology</i> , 2010, 45, 782-783.	2.3	3
131	Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients. <i>Metabolism: Clinical and Experimental</i> , 2010, 59, 64-69.	1.5	25
132	Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis. <i>Metabolism: Clinical and Experimental</i> , 2010, 59, 1327-1330.	1.5	93
133	Microalbuminuria and nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2010, 59, e6.	1.5	1
134	Folic Acid and Vitamin B12 Supplementation Improves Coronary Flow Reserve in Elderly Subjects with Vitamin B12 Deficiency. <i>Archives of Medical Research</i> , 2010, 41, 369-372.	1.5	11
135	Molecular signatures of nonalcoholic fatty liver disease: The present and future. <i>Hepatology</i> , 2010, 51, 1866-1866.	3.6	0
136	Cigarette smoking is not associated with specific histological features or severity of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010, 52, 391-391.	3.6	14
137	Liver enzymes and cardiovascular outcomes: A new research agenda. <i>Hepatology</i> , 2010, 52, 2242-2242.	3.6	1
138	Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. <i>European Journal of Clinical Investigation</i> , 2010, 40, 887-892.	1.7	159
139	Serum fetuin A and 2HS-glycoprotein levels in patients with non-alcoholic fatty liver disease: relation with liver fibrosis. <i>Annals of Clinical Biochemistry</i> , 2010, 47, 549-553.	0.8	56
140	Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2010, 70, 541-546.	0.6	38
141	Apoptosis in nonalcoholic steatohepatitis with normal aminotransferase values: zooming in on cytokeratin 18 fragments. <i>Biomarkers in Medicine</i> , 2010, 4, 743-745.	0.6	4
142	Caspase-cleaved fragments of cytokeratin 18 in patients with chronic hepatitis B. <i>Clinica Chimica Acta</i> , 2010, 411, 2029-2032.	0.5	12
143	Coronary flow reserve is impaired in patients with nonalcoholic fatty liver disease: Association with liver fibrosis. <i>Atherosclerosis</i> , 2010, 211, 182-186.	0.4	84
144	Liver function tests: Association with cardiovascular outcomes. <i>World Journal of Hepatology</i> , 2010, 2, 143.	0.8	8

#	ARTICLE	IF	CITATIONS
145	Serum Levels of Adipokines in Patients with Chronic HCV Infection: Relationship with Steatosis and Fibrosis. <i>Archives of Medical Research</i> , 2009, 40, 294-298.	1.5	28
146	The quest for liver fibrosis biomarkers: Promises from the enhanced liver fibrosis panel and beyond. <i>Hepatology</i> , 2009, 49, 1056-1057.	3.6	4
147	Serum M30 levels: A potential biomarker of severe liver disease in nonalcoholic fatty liver disease and normal aminotransferase levels. <i>Hepatology</i> , 2009, 49, 697-697.	3.6	16
148	Liver disease as a risk factor for cognitive decline and dementia: An Under-recognized issue. <i>Hepatology</i> , 2009, 49, 698-698.	3.6	27
149	“Defragmenting” the noninvasive diagnosis of nonalcoholic steatohepatitis: Hopes from cytokeratin-18. <i>Hepatology</i> , 2009, 50, 990-991.	3.6	1
150	Metformin, hepatitis C, and insulin resistance: Sufficient evidence?. <i>Hepatology</i> , 2009, 50, 2054-2055.	3.6	1
151	Comments on: Goodness-of-fit tests in mixed models. <i>Test</i> , 2009, 18, 256-259.	0.7	3
152	ORIGINAL ARTICLE: Human Serum Complement C3 and Factor H in the Syndrome of Hemolysis, Elevated Liver Enzymes, and Low Platelet Count. <i>American Journal of Reproductive Immunology</i> , 2009, 62, 238-242.	1.2	5
153	Derivatization and in situ metallation of phthalocyanines using click chemistry. <i>Polyhedron</i> , 2009, 28, 3419-3424.	1.0	27
154	Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease. <i>Clinical Biochemistry</i> , 2009, 42, 802-807.	0.8	58
155	Proteomic analysis of serum in patients with non-alcoholic steatohepatitis using matrix-assisted laser desorption ionization time-of-flight mass spectrometry. <i>Scandinavian Journal of Gastroenterology</i> , 2009, 44, 1471-1476.	0.6	14
156	Small arterial elasticity predicts the extent of coronary artery disease: Relationship with serum uric acid. <i>Atherosclerosis</i> , 2009, 202, 200-204.	0.4	15
157	Serial changes in circulating M30 antigen, a biomarker of apoptosis, in patients with acute coronary syndromes: relationship with the severity of coronary artery disease. <i>Coronary Artery Disease</i> , 2009, 20, 494-498.	0.3	10
158	Serum concentrations of human angiotensin-like protein 3 in patients with nonalcoholic fatty liver disease: association with insulin resistance. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 1247-1251.	0.8	41
159	Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis. <i>World Journal of Gastroenterology</i> , 2009, 15, 4387.	1.4	44
160	Commentary on “Cytokeratin 18, a Marker of Cell Death, is Increased in Children With Suspected Nonalcoholic Fatty Liver Disease”, <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2009, 49, 371-371.	0.9	0
161	Biomarkers for noninvasive biochemical diagnosis of nonalcoholic steatohepatitis: Tools or decorations?. <i>World Journal of Gastroenterology</i> , 2009, 15, 4346.	1.4	9
162	A “Biomarker Biopsy” for the Diagnosis of NASH: Promises from CK-18 Fragments. <i>Obesity Surgery</i> , 2008, 18, 1507-1508.	1.1	18

#	ARTICLE	IF	CITATIONS
163	Urinary IL-18: A marker of contrast-induced nephropathy following percutaneous coronary intervention?. <i>Clinical Biochemistry</i> , 2008, 41, 544-547.	0.8	43
164	The Pro12Ala polymorphism of peroxisome proliferator-activated receptor- β gene is associated with plasma levels of soluble RAGE (Receptor for Advanced Glycation Endproducts) and the presence of peripheral arterial disease. <i>Clinical Biochemistry</i> , 2008, 41, 981-985.	0.8	38
165	Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease. <i>Clinical Biochemistry</i> , 2008, 41, 1055-1058.	0.8	27
166	The β 374T/A RAGE Polymorphism Protects Against Future Cardiac Events in Nondiabetic Patients with Coronary Artery Disease. <i>Archives of Medical Research</i> , 2008, 39, 320-325.	1.5	35
167	Psychopathology in the context of obesity: The adiponectin hypothesis. <i>Medical Hypotheses</i> , 2008, 70, 902-903.	0.8	8
168	The LPA gene C93T polymorphism influences plasma lipoprotein(a) levels and is independently associated with susceptibility to peripheral arterial disease. <i>Clinica Chimica Acta</i> , 2008, 387, 109-112.	0.5	12
169	Clinical Value of the Malnutrition-Inflammation-Atherosclerosis Syndrome for Long-Term Prediction of Cardiovascular Mortality in Patients with End-Stage Renal Disease: A 5-Year Prospective Study. <i>Nephron Clinical Practice</i> , 2008, 108, c99-c105.	2.3	53
170	Acute myocardial infarction, ischemic cerebrovascular disease and variceal bleeding due to portal vein thrombosis in a patient with hereditary thrombophilia. <i>Blood Coagulation and Fibrinolysis</i> , 2008, 19, 243-246.	0.5	1
171	Predictive value of the modified Early Warning Score in a Turkish emergency department. <i>European Journal of Emergency Medicine</i> , 2008, 15, 338-340.	0.5	36
172	Effect of intensive statin therapy on arterial elasticity in patients with coronary artery disease. <i>Acta Cardiologica</i> , 2008, 63, 467-471.	0.3	7
173	Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. <i>World Journal of Gastroenterology</i> , 2007, 13, 837.	1.4	165
174	Clinical significance of activity of ALT enzyme in patients with hepatitis C virus. <i>World Journal of Gastroenterology</i> , 2007, 13, 5481.	1.4	33